<DOC>
	<DOCNO>NCT00851266</DOCNO>
	<brief_summary>This first man study evaluate tolerability immunogenicity BIPCV/IMX ( V512 ) increase concentration influenza viral peptide A/M2+B/HA0 peptide IMX , saponin-based adjuvant .</brief_summary>
	<brief_title>A Study Bivalent Influenza Peptide Conjugate Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject good physical health Subject category individual recommend CDC receive influenza vaccine upcoming 2 influenza season Subject agree seek vaccination license influenza vaccine study Female subject agree use acceptable birth control 6 week prior first dose vaccine 1 month post Dose 3 Subject history allergic reaction vaccine component Subject fever within 3 day screen Subject vaccination inactive virus within 14 day Dose 1 Subject vaccination live virus within 30 day Dose 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>